OMNICEF Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Omnicef, and when can generic versions of Omnicef launch?
Omnicef is a drug marketed by Abbvie and is included in two NDAs.
The generic ingredient in OMNICEF is cefdinir. There are twelve drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the cefdinir profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Omnicef
A generic version of OMNICEF was approved as cefdinir by LUPIN on May 19th, 2006.
Summary for OMNICEF
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 2 |
Raw Ingredient (Bulk) Api Vendors: | 68 |
Clinical Trials: | 14 |
Patent Applications: | 4,966 |
Formulation / Manufacturing: | see details |
DailyMed Link: | OMNICEF at DailyMed |
Recent Clinical Trials for OMNICEF
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
St. Joseph's Hospital and Medical Center, Phoenix | Phase 4 |
Thomas Jefferson University | Phase 4 |
The Cleveland Clinic | Phase 4 |
Anatomical Therapeutic Chemical (ATC) Classes for OMNICEF
US Patents and Regulatory Information for OMNICEF
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Abbvie | OMNICEF | cefdinir | CAPSULE;ORAL | 050739-001 | Dec 4, 1997 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Abbvie | OMNICEF | cefdinir | FOR SUSPENSION;ORAL | 050749-001 | Dec 4, 1997 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Abbvie | OMNICEF | cefdinir | FOR SUSPENSION;ORAL | 050749-002 | Jul 29, 2004 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for OMNICEF
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Abbvie | OMNICEF | cefdinir | FOR SUSPENSION;ORAL | 050749-002 | Jul 29, 2004 | ⤷ Try a Trial | ⤷ Try a Trial |
Abbvie | OMNICEF | cefdinir | CAPSULE;ORAL | 050739-001 | Dec 4, 1997 | ⤷ Try a Trial | ⤷ Try a Trial |
Abbvie | OMNICEF | cefdinir | FOR SUSPENSION;ORAL | 050749-001 | Dec 4, 1997 | ⤷ Try a Trial | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for OMNICEF
See the table below for patents covering OMNICEF around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Austria | 123221 | ⤷ Try a Trial | |
South Korea | 970008126 | ⤷ Try a Trial | |
Spain | 2072856 | ⤷ Try a Trial | |
Hong Kong | 18496 | Novel crystalline 7-(2-(2-aminothiazol-4-yl)-2-hydroxyimino-acetamido)-3-vinyl-3-cephem-4-carboxzlic acid (synisomer) | ⤷ Try a Trial |
European Patent Office | 0304019 | Acide cristallin 3-céphem-4 carboxylique 7-(2-(2-aminothiazol-4-yl)-2-hydroxyiminoacétamido)-3-vinyle (isomère syn). (Novel crystalline 7-(2-(2-aminothiazol-4-yl)-2-hydroxyiminoacetamido)-3-vinyl-3-cephem-4-carboxylic acid (syn isomer).) | ⤷ Try a Trial |
Ireland | 882411 | ⤷ Try a Trial | |
Australia | 617347 | ⤷ Try a Trial | |
>Country | >Patent Number | >Title | >Estimated Expiration |